Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Liabilities: 2017-2024

Historic Total Liabilities for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $64.8 million.

  • Aclaris Therapeutics' Total Liabilities rose 6.11% to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.4 million, marking a year-over-year increase of 6.11%. This contributed to the annual value of $64.8 million for FY2024, which is 61.02% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Total Liabilities of $64.8 million as of FY2024, which was up 61.02% from $40.2 million recorded in FY2023.
  • Aclaris Therapeutics' Total Liabilities' 5-year high stood at $64.8 million during FY2024, with a 5-year trough of $33.1 million in FY2020.
  • For the 3-year period, Aclaris Therapeutics' Total Liabilities averaged around $54.0 million, with its median value being $57.0 million (2022).
  • In the last 5 years, Aclaris Therapeutics' Total Liabilities skyrocketed by 62.58% in 2021 and then decreased by 29.40% in 2023.
  • Over the past 5 years, Aclaris Therapeutics' Total Liabilities (Yearly) stood at $33.1 million in 2020, then spiked by 62.58% to $53.9 million in 2021, then increased by 5.76% to $57.0 million in 2022, then decreased by 29.40% to $40.2 million in 2023, then surged by 61.02% to $64.8 million in 2024.